FDA Can Help On Drug Prices – Except When It Can't, Califf Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Commissioner nominee tells Senate that faster approvals of cheap products and quicker development of innovative ones will reduce pricing pressure; 'monopoly' positions are a concern, but Califf draws the line when asked about drug importation.
You may also be interested in...
Califf Confirmation Hearing Round Two: Industry Ties Once Again May Bark Loud, Bite Lightly
The cardiologist seeking another term as FDA commissioner has been working in the pharma industry since leaving the post, but Senators have tended not to question nominee's work history extensively during previous confirmation hearings.
Califf Confirmation Hearing Round Two: Industry Ties Once Again May Bark Loud, Bite Lightly
The cardiologist seeking another term as FDA commissioner has been working in the pharma industry since leaving the post, but Senators have tended not to question nominee's work history extensively during previous confirmation hearings.
Rx Importation: Califf's Switch Means US FDA Commissioners No Longer Uniformly Opposed
In JAMA editorial, former FDA chief supports drug importation under narrow circumstances as a way to reduce drug prices, marking a shift from his previous stance on the issue and that of other past agency heads. Essay, co-authored by former CMS Acting Administrator Andy Slavitt, calls importation "a workaround born of desperation."